PsychonautWiki Archive

3-HO-PCE: Difference between revisions

← Older editNewer edit →
>Unity
m Clarity moved page Talk:3-HO-PCE to 3-HO-PCE without leaving a redirect: Published.
>Unity
Minor intro expansion. Some effects updating.
Line 4: Line 4:
'''3-Hydroxyeticyclidine''' (commonly known as '''3-HO-PCE''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class that produces potent, dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. Unlike its close structural analog [[3-HO-PCP]], this compound is entirely novel and has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.  
'''3-Hydroxyeticyclidine''' (commonly known as '''3-HO-PCE''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class that produces potent, dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. Unlike its close structural analog [[3-HO-PCP]], this compound is entirely novel and has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.  


Early discussions of this compound have revolved around whether it possesses an appreciable affinity for the [[μ-opioid]] [[receptor]] given its structural relationship to [[3-HO-PCP]], which is known to possess affinity for the  [[μ-opioid]] [[receptor]].<ref name="3HOPCEsar">Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O. Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.</ref> Whether it produces any of its theorized [[opioid]] effects in humans is the subject of ongoing discussion.  
Early discussions of this compound have revolved around whether it possesses an appreciable affinity for the [[μ-opioid]] [[receptor]] given its structural relationship to [[3-HO-PCP]], which has been shown to display affinity for the  [[μ-opioid]] [[receptor]] in animal models.<ref name="3HOPCEsar">Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O. Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.</ref> Whether it produces any of its theorized [[opioid]] effects in humans is the subject of ongoing discussion. If it does, 3-HO-PCE may pose unique risks relative to other dissociatives, particularly when it is redosed.


Following other substances of its class, particularly [[methoxetamine]] (MXE), [[phencyclidine]] (PCP), and [[3-MeO-PCE]], it is speculated to to be able to induce a state known as "[[dissociatives#Subjective effects|dissociative anesthesia]]". Early reports suggest that this state is difficult to reach relative to other [[dissociatives]], and its general effects profile been characterized as "lying halfway between [[3-MeO-PCP]] and [[3-MeO-PCE]]."  
Following other substances of its class, particularly [[methoxetamine]] (MXE), [[phencyclidine]] (PCP), and [[3-MeO-PCE]], it is speculated to to be able to induce a state known as "[[dissociatives#Subjective effects|dissociative anesthesia]]". Early reports suggest that this state is difficult to reach relative to other [[dissociatives]], and its general effects profile been characterized as "lying halfway between [[3-MeO-PCP]] and [[3-MeO-PCE]]."  
There are also reports that suggest this compound may produce more physical side effects such as muscle soreness and flu-like symptoms during or shortly after administration. This suggests it may be uniquely more dangerous or toxic than related [[dissociatives]], particularly at higher doses.


There is a complete lack of data on the pharmacological properties, metabolism, and toxicity of 3-HO-PCE, and it has an extremely brief history of human usage. Today, it is exclusively distributed as a gray area [[research chemical]] by online vendors.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> Due to its potent [[dissociative]] and [[opioid]] effects, potential habit-forming properties, and unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.
There is a complete lack of data on the pharmacological properties, metabolism, and toxicity of 3-HO-PCE, and it has an extremely brief history of human usage. Today, it is exclusively distributed as a gray area [[research chemical]] by online vendors.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> Due to its potent [[dissociative]] and [[opioid]] effects, potential habit-forming properties, and unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.
Line 31: Line 29:


|{{effects/physical|
|{{effects/physical|
 
The physical effects of this substance have been reported to be relatively unpronounced or difficult to detect.
*'''[[Effect::Stimulation]]''' & '''[[Effect::Sedation]]'''
*'''[[Effect::Stimulation]]''' & '''[[Effect::Sedation]]'''
*'''[[Effect::Spontaneous physical sensations]]'''
*'''[[Effect::Physical euphoria]]''' - 3-HO-PCE has been reported to more readily induce euphoria than most other dissociatives, such as [[ketamine]] or [[diphenidine]], especially of the manic variant.
*'''[[Effect::Tactile enhancement]]''' & '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Tactile enhancement]]''' & '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only at higher doses.
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only at higher doses.
Line 40: Line 36:
*'''[[Effect::Changes in felt gravity]]'''
*'''[[Effect::Changes in felt gravity]]'''
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Increased blood pressure]]'''  
*'''[[Effect::Increased blood pressure]]'''  
*'''[[Effect::Increased heart rate]]'''  
*'''[[Effect::Increased heart rate]]'''  
Line 68: Line 63:
*'''[[Effect::Compulsive redosing]]''' - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
*'''[[Effect::Compulsive redosing]]''' - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Mania]]''' - This effect is reportedly more common on 3-HO-PCE than most other dissociatives.  
*'''[[Effect::Mania]]''' - This effect is reportedly more common on 3-HO-PCE than most other dissociatives.  
*'''[[Effect::Depersonalization]]'''
*'''[[Effect::Depersonalization]]'''
Line 76: Line 69:
*'''[[Effect::Psychosis]]'''  
*'''[[Effect::Psychosis]]'''  
*'''[[Effect::Delusions]]'''
*'''[[Effect::Delusions]]'''
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Cognitive euphoria]]'''
*'''[[Effect::Cognitive euphoria]]'''
*'''[[Effect::Memory suppression]]'''  
*'''[[Effect::Memory suppression]]'''  
Line 97: Line 89:


*'''[[Effect::Visual acuity suppression]]''' - While lower doses of this compound may produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increase.
*'''[[Effect::Visual acuity suppression]]''' - While lower doses of this compound may produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increase.
*'''[[Effect::Double vision]]'''
*'''[[Effect::Frame rate suppression]]'''
*'''[[Effect::Frame rate suppression]]'''
*'''[[Effect::Pattern recognition suppression]]'''
*'''[[Effect::Pattern recognition suppression]]'''
Line 163: Line 154:
*[[Arylcyclohexylamines]]
*[[Arylcyclohexylamines]]
*[[3-MeO-PCP]]
*[[3-MeO-PCP]]
*[[3-HO-PCP]]
*[[PCP]]
*[[PCP]]


Retrieved from "http://psy.st/wiki/3-HO-PCE"